BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1569294)

  • 1. Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.
    Pontiroli AE; Lanzi R; Monzani M; Musatti L; Guglielmone C; Pozza G
    J Endocrinol Invest; 1992 Feb; 15(2):85-91. PubMed ID: 1569294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.
    Andreotti AC; Lanzi R; Manzoni MF; Caumo A; Moreschi A; Pontiroli AE
    Metabolism; 1994 Oct; 43(10):1207-13. PubMed ID: 7934970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin.
    Pontiroli AE; Lanzi R; Monti LD; Sandoli E; Pozza G
    J Clin Endocrinol Metab; 1991 Feb; 72(2):492-5. PubMed ID: 1671389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth hormone clamp technique: inhibition of growth hormone release by growth hormone occurs independently of free fatty acids.
    Lanzi R; Pontiroli AE; Monti LD; Monzani M; Pozza G
    Metabolism; 1990 Aug; 39(8):819-21. PubMed ID: 2198432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
    Pontiroli AE; Lanzi R; Monti LD; Pozza G
    J Endocrinol Invest; 1990 Jun; 13(6):539-42. PubMed ID: 2258583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects.
    Lanzi R; Manzoni MF; Andreotti AC; Malighetti ME; Bianchi E; Sereni LP; Caumo A; Luzi L; Pontiroli AE
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2239-43. PubMed ID: 9215300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The control on growth hormone release by free fatty acids is maintained in acromegaly.
    Lanzi R; Losa M; Mignogna G; Caumo A; Pontiroli AE
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1234-8. PubMed ID: 10199760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
    Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
    Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
    Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
    Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of growth hormone (GH) on glycerol and free fatty acid metabolism during exhaustive exercise in GH-deficient adults.
    Gibney J; Healy ML; Stolinski M; Bowes SB; Pentecost C; Breen L; McMillan C; Russell-Jones DL; Sonksen PH; Umpleby AM
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1792-7. PubMed ID: 12679475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans.
    Djurhuus CB; Gravholt CH; Nielsen S; Pedersen SB; Møller N; Schmitz O
    Am J Physiol Endocrinol Metab; 2004 Mar; 286(3):E488-94. PubMed ID: 14600073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of basal glucose metabolism and insulin sensitivity by growth hormone and free fatty acids during short-term fasting.
    Nørrelund H; Nielsen S; Christiansen JS; Jørgensen JO; Møller N
    Eur J Endocrinol; 2004 Jun; 150(6):779-87. PubMed ID: 15191347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term met-hGH infusion inhibits somatotroph response to growth hormone releasing hormone (1-44).
    Rosenbaum M; Loche S; Balzano S; Gertner JM
    Metabolism; 1988 Feb; 37(2):131-5. PubMed ID: 3123873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.
    Vickers MH; Hofman PL; Gluckman PD; Lobie PE; Cutfield WS
    Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1212-9. PubMed ID: 16803850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
    Saloranta C; Taskinen MR; Widen E; Härkönen M; Melander A; Groop L
    Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.